@article{5cd85ad25cfd453dbdbf33e81ee907a5,
title = "Outcome of allogeneic hematopoietic stem cell transplantation for mycosis fungoides and S{\'e}zary syndrome",
abstract = "Although allogeneic hematopoietic stem cell transplantation (HSCT) has been reported to provide prolonged remission of relapsed/refractory mycosis fungoides (MF) and S{\'e}zary syndrome (SS), its role has not been fully evaluated. Here, the outcomes of allogeneic HSCT for patients with MF/SS were retrospectively evaluated by using the registry database of the Japan Society for Hematopoietic Cell Transplantation. Forty-eight patients were evaluable and enrolled in the analysis. Median age was 45.5 years. Eighteen patients (38%) received myeloablative conditioning, and 33 (69%) received HSCT from an alternative donor. Disease status was complete or partial response in 25% of the patients and relapsed or refractory in the others. At the time of analysis, 18 patients were alive, with a median follow-up of 31.0 months (range, 3.8-31.1). Three-year overall survival (OS) and progression-free survival (PFS) were 30% (95%CI, 16-45%) and 19% (95%CI, 9-31%), respectively. Disease progression was not observed later than 17 months after transplantation. Both disease status and performance status at transplant significantly affected OS and PFS. Although our findings suggest that allogeneic HSCT provides long-term PFS in patients with MF/SS, the timing of transplantation should be decided carefully based on the disease status and the patient's condition in order to improve the outcome.",
keywords = "S{\'e}zary syndrome, allogeneic hematopoietic stem cell transplantation, mycosis fungoides",
author = "Takehiko Mori and Souichi Shiratori and Junji Suzumiya and Mineo Kurokawa and Motohiro Shindo and Uchida Naoyuki and Takenaka Katsuto and Toshihiro Miyamoto and Satoshi Morishige and Makoto Hirokawa and Takahiro Fukuda and Yoshiko Atsuta and Ritsuro Suzuki",
note = "Funding Information: T.M. received research funding from MSD, Novartis Pharma, LSI Medience, Medical and Biological Laboratories, and Asahi Kasei Corporation, and personal fees from Pfizer, MSD, Janssen Pharma, Sumitomo Dainippon Pharma, Novartis Pharma, Kyowa Kirin, Chugai Pharmaceutical, Shionogi and Co., Japan Blood Products Organization, Takeda Pharmaceutical, Ono Pharmaceutical, Shire, Eisai, and Astellas Pharma. J.S. received research funding Celgene, Kyowa Hakko Kirin, Chugai‐Roche, Eisai, Takeda, Celltrion, SymBio, Astellas, Ono, AstraZeneca, Ootsuka, Taiho, Mundi, and Dainihon‐Sumitomo, and personal fees from Chugai‐Roche, Celgene, Janssen, Takeda, Bristol Myers Squibb, Dainihon‐Sumitomo, Nihonshinyaku, Taiho, Abbie, Eisai, Celgene, Zenyaku, Novartis, Eli Lilly, AstraZeneca, Pfizer, Bioverativ, and MSD. Y.A. received an honorarium from Mochida Pharmaceutical, Meiji Seika Pharma, Chugai Pharmaceutical, and Kyowa Kirin. R.S. received honoraria from Bristol‐Meyers Squibb, Novartis, Kyowa‐Hakko Kirin, Chugai Pharmaceuticals, Shionogi, Takeda, Meiji Seika Pharma, MSD, Ohtsuka, Sawai, Celgene, Sumitomo Dainippon, Eisai Pharmaceuticals, Alexion Pharma, Sanofi, Ono Pharma, and Janssen, and a consultancy from Gilead Sciences, Abbvie, Mundi Pharma, and Jazz Pharma. Funding Information: The authors would like to thank all the physicians and data managers at each transplant center and the staff members of the Japanese Data Center for Hematopoietic Cell Transplantation. This work was supported in part by the Practical Research Project for Allergic Diseases and Immunology (Research Technology of Medical Transplantation) from the Japan Agency for Medical Research and Development, AMED, under grant number 19ek0510023h0002. Publisher Copyright: {\textcopyright} 2020 John Wiley & Sons Ltd",
year = "2020",
month = aug,
day = "1",
doi = "10.1002/hon.2719",
language = "English",
volume = "38",
pages = "266--271",
journal = "Hematological Oncology",
issn = "0278-0232",
publisher = "John Wiley and Sons Ltd",
number = "3",
}
